The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Open accessAbstract
Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent sorafenib in 2007. Although sorafenib expanded the treatment options for extrahepatic spread (EHS) and vascular invasion, making long-term survival of patients with advanced disease achievable to a certain extent, new molecular-targeted agents are being developed as alternatives to sorafenib due to shortcomings such as its low response rate and high toxicity. Every single one of the many drugs developed during the 10-year period from 2007 to 2016 was a failure. However, during the two-year period from 2017 through 2018, four drugs—regorafenib, lenvatinib, cabozantinib, and ramucirumab—emerged successfully from clinical trials in quick succession and became available for clinical use. The efficacy of combination therapy with transcatheter arterial chemoembolization (TACE) plus sorafenib was also first demonstrated in 2018. Recently, immune checkpoint inhibitors have been applied to HCC treatment and many phase III clinical trials are ongoing, not only on monotherapy with nivolumab, pembrolizumab, and tislelizumab, but also on combination therapy with checkpoint inhibitors, programmed death-1 (PD-1) or PD-ligand 1 (PD-L1) antibody plus a molecular targeted agent (bevacizumab) or the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody, tremelimumab. These combination therapies have shown higher response rates than PD-1/PD-L1 monotherapy alone, suggesting a synergistic effect by combination therapy in early phases; therefore, further results are eagerly awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 3×
“Efficacy Nivolumab [52] Pembrolizumab [54] Pembrolizumab Plus Lenvatinib [55] Atezolizumab Plus Bevacizumab [56] SHR-1210 Plus Apatinib [57] Durvalumab Plus Tremelimumab [58]”
BackgroundResultSelf-citationCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 3×
“Durvalumab is being developed for combination therapy with the anti–CTLA-4 antibody, tremelimumab [58].”
BackgroundWilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Self-citationYamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
Yoshida, H., Shiratori, Y., Kudo, M., Shiina, S., Mizuta, T., Kojiro, M., Yamamoto, K., Koike, Y., Saito, K., Koyanagi, N., et al. (2011) · Hepatology · doi:10.1002/hep.24430 · Cited by 127 · cited 2×
“Three phase III trials, one comparing vitamin K2 with placebo as adjuvant chemotherapy after radiofrequency ablation or resection [6], one comparing sorafenib with placebo (STORM trial) [7], one comparing peretinoin with placebo (NIK333 trial) [8], and one comparing ablation plus lyso-thermosensitive liposomal doxorub…”
BackgroundMethodSelf-citationPeretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0956-9 · Cited by 90
Self-citation
Cited by
Molecular and histological correlations in liver cancer
Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.001 · Cited by 590
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., & Omata, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061358 · Cited by 280
Immunotherapy for hepatocellular carcinoma
Zongyi, Y., & Xiaowu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 265
Deng, H., Kan, A., Lyu, N., Mu, L., Han, Y., Liu, L., Zhang, Y., Duan, Y., Liao, S., Li, S., et al. (2020) · Liver Cancer · doi:10.1159/000505695 · Cited by 173
Metadata
- Authors
- Kudo, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-10-30
- Volume
- 10
- Issue
- 11
- Pages
- 412
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2898616210
- Cited by
- 172
- References
- 10
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. https://app.cochat.ai/papers/10.3390/cancers10110412
- The paper
- Kudo, M. (2018). Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers. https://doi.org/10.3390/cancers10110412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.